the manuscript itself, the confusion increases. When addressing the question, 'can we define a safe level of intake regarding adding GLU?' the authors state, 'based on dietary animal studies (metabolic control), a 'no observed adverse effect level' of 16000 mg/kg body weight was calculated in weaning animals y'. Yet, on page 7, evidence is cited that 'the oral dose that is lethal to 50% of subjects (LD50) in rats and mice is 15 000-18 000 mg/kg bw, respectively'. This is difficult to understand.
Even when disregarding misprints, the consensus paper is far from being a consensus. In 1995, Monno et al. (1995) studied the effect of high doses of monosodium glutamate (MSG) on the extracellular concentration of glutamate (GLU) in the hypothalamus and in the hippocampus of freely moving rats. MSG at 4 g/kg (40% solution) given by gavage caused a significant increase in plasma (5.370.4-fold, Po0.01) and extracellular GLU in the hippocampus (4.270.6-fold, Po0.01) and in the hypothalamus (8.971.7-fold, Po0.01) compared to control rats receiving a 40% sucrose solution (10 ml/kg). The peak increase was found within 40 min after MSG administration, then declining to baseline in the next 80 min. In 1995 , Currie et al. (1995 examined paraventricular nucleus extracellular amino-acid concentrations in awake, freely behaving rats following gavage of equicaloric loads of a balanced amino-acid mixture, glucose (0.89 g) or water. Dialysate levels of GLU, isoleucine, leucine, methionine, threonine, tyrosine and valine showed reliable increases after amino-acid treatment. The authors concluded that specific brain regions may respond uniquely to amino-acid ingestion and further imply that dietary composition may influence the amino-acid profiles of the extracellular fluid in brain.
We studied the effect of oral administration of MSG to pregnant rats on birth weight of the offspring (Hermanussen et al., 2006) . Maternal feeding with 5 g MSG per day resulted in severe birth weight reduction (Po0.01). Also growth hormone (GH) serum levels were affected in animals that received MSG during prenatal life via maternal feeding.
Animals that are kept on high-MSG diet (5 g MSG per day) continue to show serum GH levels that are as low or even lower than those of MSG-injected animals (Po0.05), both at day 30 and at day 90 of life. Animals that were kept on medium-MSG diet (2.5 g MSG per day) showed low serum GH levels at day 30 of life (Po0.01), but seemed to partially recover before day 90.
In summary, current evidence suggests that orally administered GLU passes into the circulation and enters the central nervous system, possibly even in fetuses whose mothers are fed GLU. Very recent evidence has been added by Cheunsuang et al. (2006) , who showed that the medial arcuate nucleus, that is an area that attributes to feeding control, belongs to those regions of the CNS that take up molecules from the circulation.
Thus, I must disagree when it is stated that, 'as long as BBB is intact there is no risk for GLU transfer across BBB'. Home parenteral nutrition (HPN) is a life-saving strategy in patients with severe intestinal failure. However, the quality of life of these patients remains to be compromised by the frequent development of technique-related complications, especially catheter infections and liver failure. We present a case that shows that not all patients suffer from these problems and that arteriovenous fistulae (AVF) can be suitable means to deliver HPN. A female patient underwent a near-total small bowel resection at the age of 26 years because of acute intestinal ischemia, caused by a malrotation. The remaining duodenum was anastomosed to the transverse colon. Parenteral nutrition was initiated over an AVF, created on the left forearm from bovine graft material. Six months later, she acutely developed a severe septic shock after using a bag of nutrition that was contaminated by Streptococcus viridans. Her AVF occluded during this period and a second bovine graft AVF was created on the right forearm. Six years later, this AVF became occluded and a third AVF was created on the right forearm with autologous material (saphenous vein). Two central lines that were used during the maturation of her shunts had to be prematurely removed owing to catheter sepsis, caused by Staphylococcus aureus. Ever since, 25 years after the creation of the third AVF and 31 years after the initiation of HPN, there have been no major events and she is currently doing very well. She has developed minor cholestasis, with a recent liver biopsy showing discrete steatosis, fibrosis and chronic portal tract inflammation, but no cirrhosis. Intravenous warfarin (as anticoagulant because of her shunt) and alendronate (because of osteoporosis of the lumbar spine) comprise her medications at this point.
M Hermanussen
To our knowledge, our center is unique in the world by using AVF to deliver HPN on a regular basis. We have previously reported on our experience and concluded that AVF are valuable alternatives for central venous catheters (Engels et al., 1983) . Ever since, the information on the use of AVF for this indication has remained anecdotal (Baird et al., 1980) . Our actual HPN population comprises 61 patients out of whom 20 (33%) use AVF and 37 (61%) have used an AVF at some point during their treatment. The uneventful course of our patient after her first problematic years is remarkable, certainly when one realizes that catheter sepsis and occlusion in HPN patients occur with reported frequencies of 0.34 and 0.071 episodes per catheter year, respectively (Howard and Ashley, 2003) .
In our experience, the potential disadvantage of surgically created fistulae (an increased risk for vascular occlusion with the need for surgical desobstruction) outweighs the severely increased risk for infectious complications that we see with central lines. Importantly, all our patients with AVF are on anticoagulant therapy.
Over the years, our patient has developed mildly cholestatic liver function tests, without evidence for liver failure, and osteoporosis, without fractures or decreased height. These abnormalities are not unexpected, since liver problems (severe or mild) and metabolic bone disease are observed with frequencies of 0.024, 0.42 and 0.05 per year of HPN, respectively (Howard and Ashley, 2003) .
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